SRR1336887
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1443955 | GTEX | — | 0.952 |
| 2 | SRR1486496 | GTEX | — | 0.944 |
| 3 | SJEPD001523_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.943 |
| 4 | SRR1370473 | GTEX | — | 0.937 |
| 5 | SRR1457551 | GTEX | — | 0.936 |
| 6 | SRR1500617 | GTEX | — | 0.934 |
| 7 | SRR1432765 | GTEX | — | 0.924 |
| 8 | BS_EXYHZ6D4 | pilocytic astrocytoma | — | 0.923 |
| 9 | SRR1456294 | GTEX | — | 0.922 |
| 10 | SRR662091 | GTEX | — | 0.921 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.452 | Remibrutinib | — uncovered |
| COAGULATION | 0.333 | Binimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.333 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.327 | Cobimetinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.269 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.220 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.217 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.179 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.168 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.122 | Inavolisib | — uncovered |
| MYOGENESIS | 0.095 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.094 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.065 | Inavolisib | — uncovered |
| COMPLEMENT | 0.063 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.062 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.049 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.012 | Temsirolimus | — uncovered |